Multiple Sclerosis Drugs - Lesotho

Lesotho

The revenue in the Multiple Sclerosis Drugs market in Lesotho is projected to reach US$0.40m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 1.46%, resulting in a market volume of US$0.43m by 2029.
In global comparison, United States will generate the most revenue, reaching US$11,770.00m in 2024.
Despite its small size and limited resources, Lesotho has shown a growing interest in the development and availability of innovative multiple sclerosis drugs.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for multiple sclerosis drugs in Lesotho has been increasing steadily over the past few years.

Customer preferences: Lesotho has a relatively small population, and the prevalence of multiple sclerosis is low. However, there is a growing awareness of the disease among healthcare professionals and patients, which has led to an increase in demand for multiple sclerosis drugs. Patients in Lesotho prefer drugs that are effective and affordable.

Trends in the market: The multiple sclerosis drugs market in Lesotho is dominated by a few multinational pharmaceutical companies. These companies have been introducing new drugs to the market, which has increased the competition. The market has also been growing due to the increasing prevalence of multiple sclerosis in the region.

Local special circumstances: Lesotho is a small, landlocked country that relies heavily on South Africa for its imports. This has made it difficult for pharmaceutical companies to enter the market, as they have to navigate complex regulatory processes and supply chain issues. However, the government of Lesotho has been working to improve the regulatory environment and attract more investment to the country.

Underlying macroeconomic factors: Lesotho is one of the poorest countries in the world, with a high level of poverty and unemployment. This has limited the ability of patients to afford expensive drugs, and has also made it difficult for pharmaceutical companies to invest in the country. However, the government has been implementing policies to promote economic growth and improve access to healthcare, which could lead to increased demand for multiple sclerosis drugs in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.